Protection of glucagon-like peptide-1 in cisplatin-induced renal injury elucidates gut-kidney connection

Journal of the American Society of Nephrology

Volumn 24, Issue 12, 2013, Pages 2034-2043

  Katagiri, Daisuke ^a   Hamasaki, Yoshifumi ^a   Doi, Kent ^a   Okamoto, Koji ^a   Negishi, Kousuke ^a   Nangaku, Masaomi ^a   Noiri, Eisei ^a,b  

^a UNIVERSITY OF TOKYO   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALOGLIPTIN; BIM PROTEIN; CASPASE 3; CISPLATIN; CREATININE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; MESSENGER RNA; NEUROPEPTIDE; PROTEIN BAX; PROTEIN BCL 2; SINGLE STRANDED DNA; SMALL INTERFERING RNA; STROMAL CELL DERIVED FACTOR 1; ANTIDIABETIC AGENT; ANTINEOPLASTIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; PEPTIDE; PIPERIDINE DERIVATIVE; URACIL; VENOM;

ACUTE KIDNEY FAILURE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; ENZYME ACTIVATION; IMMUNOASSAY; IN VIVO STUDY; KIDNEY DYSFUNCTION; KIDNEY TUBULE EPITHELIUM; KIDNEY TUBULE NECROSIS; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; RENAL PROTECTION; SIGNAL TRANSDUCTION; UREA NITROGEN BLOOD LEVEL; ACUTE KIDNEY INJURY; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; DRUG EFFECTS; GENETICS; INTESTINE; METABOLISM; PHYSIOLOGY; REPERFUSION INJURY; TOXICITY;

ACUTE KIDNEY INJURY; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CISPLATIN; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCAGON-LIKE PEPTIDE 1; HYPOGLYCEMIC AGENTS; INTESTINES; MALE; MICE; MICE, INBRED C57BL; OXIDATIVE STRESS; PEPTIDES; PIPERIDINES; RECEPTORS, GLUCAGON; REPERFUSION INJURY; RNA, SMALL INTERFERING; URACIL; VENOMS;

EID: 84889034019     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2013020134     Document Type: Article

References (54)

1. Mehta RL, Pascual MT, Gruta CG, Zhuang S, Chertow GM: Refining predictive models in critically ill patients with acute renal failure. J Am Soc Nephrol 13: 1350-1357, 2002
2. Havasi A, Borkan SC: Apoptosis and acute kidney injury. Kidney Int 80: 29-40, 2011
3. Siddik ZH: Cisplatin: Mode of cytotoxic action and molecular basis of resistance. Oncogene 22: 7265-7279, 2003
4. Pabla N, Dong Z: Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies. Kidney Int 73: 994-1007, 2008
5. Drucker DJ: The biology of incretin hormones. Cell Metab 3: 153-165, 2006
6. DuringMJ,Cao L, Zuzga DS, Francis JS, FitzsimonsHL, Jiao X, Bland RJ, Klugmann M, BanksWA, Drucker DJ, Haile CN:Glucagon-like peptide- 1 receptor is involved in learning and neuroprotection. Nat Med 9: 1173-1179, 2003
7. Bullock BP, Heller RS, Habener JF: Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 137: 2968-2978, 1996
8. Liu WJ, Jin HY, Lee KA, Xie SH, Baek HS, Park TS: Neuroprotective effect of the glucagon-like peptide-1 receptor agonist, synthetic exendin- 4, in streptozotocin-induced diabetic rats. Br J Pharmacol 164: 1410-1420, 2011
9. Sonne DP, Engstrøm T, Treiman M: Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart. Regul Pept 146: 243-249, 2008
10. Kim M, Platt MJ, Shibasaki T, Quaggin SE, Backx PH, Seino S, Simpson JA, Drucker DJ: GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. NatMed 19: 567- 575, 2013
11. Crajoinas RO,Oricchio FT, Pessoa TD, Pacheco BP, Lessa LM,MalnicG, Girardi AC: Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1. Am J Physiol Renal Physiol 301: F355-F363, 2011
12. Schlatter P, BeglingerC,Drewe J,GutmannH:Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells. Regul Pept 141: 120-128, 2007
13. Doyle ME, Egan JM: Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol Ther 113: 546-593, 2007
14. Farilla L, Hui H, Bertolotto C, Kang E, Bulotta A, Di Mario U, Perfetti R: Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 143: 4397-4408, 2002
15. Hui H, Nourparvar A, Zhao X, Perfetti R: Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 59-adenosine monophosphate-dependentprotein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway. Endocrinology 144: 1444-1455, 2003
16. Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ: Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem 278: 471-478, 2003
17. Wang Q, Brubaker PL: Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice. Diabetologia 45: 1263-1273, 2002
18. Brubaker PL: Minireview: Update on incretin biology: Focus on glucagon- like peptide-1. Endocrinology 151: 1984-1989, 2010
19. Drucker DJ: Glucagon-like peptide-1 and the islet beta-cell: Augmentation of cell proliferation and inhibition of apoptosis. Endocrinology 144: 5145-5148, 2003
20. Glorie LL, Verhulst A,Matheeussen V, Baerts L,Magielse J, Hermans N, D'Haese PC, De Meester I, De Beuf A: DPP4 inhibition improves functional outcome after renal ischemia-reperfusion injury. Am J Physiol Renal Physiol 303: F681-F688, 2012
21. Drucker DJ: Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: Preclinical biology and mechanisms of action. Diabetes Care 30: 1335-1343, 2007
22. Doi K, Suzuki Y,Nakao A, Fujita T,Noiri E: Radical scavenger edaravone developed for clinical use ameliorates ischemia/reperfusion injury in rat kidney. Kidney Int 65: 1714-1723, 2004
23. Negishi K, Noiri E, Maeda R, Portilla D, Sugaya T, Fujita T: Renal L-type fatty acid-binding protein mediates the bezafibrate reduction of cisplatin- induced acute kidney injury. Kidney Int 73: 1374-1384, 2008
24. DeMeester I, KoromS, Van Damme J, Scharpé S: CD26, let it cut or cut it down. Immunol Today 20: 367-375, 1999
25. Fleischer B: CD26: A surface protease involved in T-cell activation. Immunol Today 15: 180-184, 1994
26. Varona A, Blanco L, Perez I, Gil J, Irazusta J, López JI, Candenas ML, Pinto FM, Larrinaga G: Expression and activity profiles of DPP IV/CD26 andNEP/CD10 glycoproteins in the human renal cancer are tumor-type dependent. BMC Cancer 10: 193, 2010
27. Helbert MJ, Dauwe SE, Van der Biest I, Nouwen EJ, De Broe ME: Immunodissection of the human proximal nephron: Flowsorting of S1S2S3, S1S2 and S3 proximal tubular cells. Kidney Int 52: 414-428, 1997
28. Fadini GP, Avogaro A: Cardiovascular effects of DPP-4 inhibition: Beyond GLP-1. Vascul Pharmacol 55: 10-16, 2011
29. Tögel F, Isaac J, Hu Z, Weiss K, Westenfelder C: Renal SDF-1 signals mobilization and homing of CXCR4-positive cells to the kidney after ischemic injury. Kidney Int 67: 1772-1784, 2005
30. Jang HR, Rabb H: The innate immune response in ischemic acute kidney injury. Clin Immunol 130: 41-50, 2009
31. Gheisari Y, Azadmanesh K, Ahmadbeigi N, Nassiri SM, Golestaneh AF, Naderi M, VaseiM, Arefian E, Mirab-Samiee S, Shafiee A, SoleimaniM, Zeinali S: Genetic modification of mesenchymal stem cells to overexpress CXCR4 and CXCR7 does not improve the homing and therapeutic potentials of these cells in experimental acute kidney injury. Stem Cells Dev 21: 2969-2980, 2012
32. ZarubaMM, Theiss HD, VallasterM,Mehl U, Brunner S,David R, Fischer R, Krieg L, Hirsch E, Huber B, Nathan P, Israel L, Imhof A, Herbach N, Assmann G, Wanke R, Mueller-Hoecker J, Steinbeck G, Franz WM: Synergy between CD26/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction. Cell Stem Cell 4: 313-323, 2009
33. Murdoch C: CXCR4: Chemokine receptor extraordinaire. Immunol Rev 177: 175-184, 2000
34. Liu M, Chien CC, Burne-Taney M, Molls RR, Racusen LC, Colvin RB, Rabb H: A pathophysiologic role for T lymphocytes in murine acute cisplatin nephrotoxicity. J Am Soc Nephrol 17: 765-774, 2006
35. Karl T, Hoffmann T, Pabst R, von Hörsten S: Behavioral effects of neuropeptide Y in F344 rat substrains with a reduced dipeptidyl-peptidase IV activity. Pharmacol Biochem Behav 75: 869-879, 2003
36. Bald M, Gerigk M, Rascher W: Elevated plasma concentrations of neuropeptide Y in children and adults with chronic and terminal renal failure. Am J Kidney Dis 30: 23-27, 1997
37. Testa A, Mallamaci F, Macrì R, Pisano A, Spoto B, Malatino LS, Stancanelli B, Tripepi G, Benedetto FA, Zoccali C: Neuropeptide Y receptor Y2 gene polymorphism interacts with plasma neuropeptide Y levels in predicting left ventricular hypertrophy in dialysis patients. J Hypertens 28: 1745-1751, 2010
38. Wei Q, Dong G, Franklin J, Dong Z: The pathological role of Bax in cisplatin nephrotoxicity. Kidney Int 72: 53-62, 2007
39. JiangM, Yi X, Hsu S,Wang CY, Dong Z: Role of p53 in cisplatin-induced tubular cell apoptosis: Dependence on p53 transcriptional activity. Am J Physiol Renal Physiol 287: F1140-F1147, 2004
40. Jiang M, Wei Q, Wang J, Du Q, Yu J, Zhang L, Dong Z: Regulation of PUMA-alpha by p53 in cisplatin-induced renal cell apoptosis. Oncogene 25: 4056-4066, 2006
41. Shirakawa J, Amo K, Ohminami H, Orime K, Togashi Y, Ito Y, Tajima K, Koganei M, Sasaki H, Takeda E, Terauchi Y: Protective effects of dipeptidyl peptidase-4 (DPP-4) inhibitor against increased b cell apoptosis induced by dietary sucrose and linoleic acid in mice with diabetes. J Biol Chem 286: 25467-25476, 2011
42. Sanz C, Blázquez E: New gene targets for glucagon-like peptide-1 during embryonic development and in undifferentiated pluripotent cells. Am J Physiol Endocrinol Metab 301: E494-E503, 2011
43. Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM: Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 54: 146-151, 2005
44. Thomson SC, Kashkouli A, Singh P: Glucagon-like peptide 1 receptor stimulation increases GFR and suppresses proximal reabsorption in the rat. Am J Physiol Renal Physiol 304: F137-F144, 2013
45. Rieg T, Gerasimova M, Murray F, Masuda T, Tang T, Rose M, Drucker DJ, Vallon V: Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice. Am J Physiol Renal Physiol 303: F963-F971, 2012
46. LiW, CuiM,Wei Y, Kong X, Tang L, Xu D: Inhibition of the expression of TGF-beta1 and CTGF in human mesangial cells by exendin-4, a glucagon- like peptide-1 receptor agonist. Cell Physiol Biochem 30: 749- 757, 2012
47. Liu L, Liu J,WongWT, Tian XY, Lau CW,Wang YX, Xu G, Pu Y, Zhu Z, Xu A, Lam KS, Chen ZY, Ng CF, Yao X, Huang Y: Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism. Hypertension 60: 833-841, 2012
48. Conger JD, Falk SA, Yuan BH, Schrier RW: Atrial natriuretic peptide and dopamine in a rat model of ischemic acute renal failure. Kidney Int 35: 1126-1132, 1989
49. Nagano N, Yagi M, Kato S, Furuya Y, Miyata S, Manabe N: Renal responses to atrial natriuretic peptide (ANP) in rats with non-oliguric acute renal failure induced by cisplatin. J Vet Med Sci 57: 997-1002, 1995
50. Stoffers DA, Kieffer TJ, Hussain MA, Drucker DJ, Bonner-Weir S, Habener JF, Egan JM: Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes 49: 741-748, 2000
51. Hamasaki Y,Doi K, Okamoto K, IjichiH, SekiG,Maeda-Mamiya R, Fujita T, Noiri E: 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor simvastatin ameliorates renal fibrosis through HOXA13-USAG-1 pathway. Lab Invest 92: 1161-1167, 2012
52. Noiri E, Peresleni T, Miller F, Goligorsky MS: In vivo targeting of inducible NO synthase with oligodeoxynucleotides protects rat kidney against ischemia. J Clin Invest 97: 2377-2383, 1996
53. Conger JD, Schultz MF, Miller F, Robinette JB: Responses to hemorrhagic arterial pressure reduction in different ischemic renal failure models. Kidney Int 46: 318-323, 1994
54. Matheeussen V, Lambeir AM, JungraithmayrW, GomezN,Mc Entee K, Van der Veken P, Scharpe S, De Meester I: Method comparison of dipeptidyl peptidase IV activity assays and their application in biological samples containing reversible inhibitors. Clin Chim Acta 413: 456-462, 2012